Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Adjunct Immunotherapies for the Management of Severely Ill COVID-19 Patients
Srinivasa Reddy Bonam, Srini V. Kaveri, Anavaj Sakuntabhai, et al.
Cell Reports Medicine (2020) Vol. 1, Iss. 2, pp. 100016-100016
Open Access | Times Cited: 128

Showing 1-25 of 128 citing articles:

Single-cell landscape of bronchoalveolar immune cells in patients with COVID-19
Mingfeng Liao, Yang Liu, Jing Yuan, et al.
Nature Medicine (2020) Vol. 26, Iss. 6, pp. 842-844
Open Access | Times Cited: 2455
Treatment of 5 Critically Ill Patients With COVID-19 With Convalescent Plasma
Chenguang Shen, Zhaoqin Wang, Fang Zhao, et al.
JAMA (2020) Vol. 323, Iss. 16, pp. 1582-1582
Open Access | Times Cited: 2368
High Prevalence of Obesity in Severe Acute Respiratory Syndrome Coronavirus‐2 (SARS‐CoV‐2) Requiring Invasive Mechanical Ventilation
Arthur Simonnet, Mikaël Chetboun, Julien Poissy, et al.
Obesity (2020) Vol. 28, Iss. 7, pp. 1195-1199
Open Access | Times Cited: 2048
Observational Study of Hydroxychloroquine in Hospitalized Patients with Covid-19
Joshua D. Geleris, Yifei Sun, Jonathan Platt, et al.
New England Journal of Medicine (2020) Vol. 382, Iss. 25, pp. 2411-2418
Open Access | Times Cited: 1662
Early treatment of COVID-19 patients with hydroxychloroquine and azithromycin: A retrospective analysis of 1061 cases in Marseille, France
Matthieu Million, Jean‐Christophe Lagier, Philippe Gautret, et al.
Travel Medicine and Infectious Disease (2020) Vol. 35, pp. 101738-101738
Open Access | Times Cited: 479
Human monoclonal antibodies block the binding of SARS-CoV-2 spike protein to angiotensin converting enzyme 2 receptor
Xiangyu Chen, Li Ren, Zhiwei Pan, et al.
Cellular and Molecular Immunology (2020) Vol. 17, Iss. 6, pp. 647-649
Open Access | Times Cited: 353
Pharmaco-Immunomodulatory Therapy in COVID-19
John G. Rizk, Kamyar Kalantar‐Zadeh, Mandeep R. Mehra, et al.
Drugs (2020) Vol. 80, Iss. 13, pp. 1267-1292
Open Access | Times Cited: 275
Insights to SARS-CoV-2 life cycle, pathophysiology, and rationalized treatments that target COVID-19 clinical complications
Ioannis P. Trougakos, Κimon Stamatelopoulos, Evangelos Terpos, et al.
Journal of Biomedical Science (2021) Vol. 28, Iss. 1
Open Access | Times Cited: 240
Human immunology and immunotherapy: main achievements and challenges
Jezabel Varadé, Susana Magadán, África González‐Fernández
Cellular and Molecular Immunology (2020) Vol. 18, Iss. 4, pp. 805-828
Open Access | Times Cited: 151
Flattening the COVID-19 Curve With Natural Killer Cell Based Immunotherapies
Marisa Market, Leonard Angka, Andre B. Martel, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 145
Symptomatic Protective Action of Glycyrrhizin (Licorice) in COVID-19 Infection?
Harald Murck
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 133
Clinical efficacy of intravenous immunoglobulin therapy in critical ill patients with COVID‐19: a multicenter retrospective cohort study
Ziyun Shao, Yong-wen Feng, Li Zhong, et al.
Clinical & Translational Immunology (2020) Vol. 9, Iss. 10
Open Access | Times Cited: 133
The recent challenges of highly contagious COVID‐19, causing respiratory infections: Symptoms, diagnosis, transmission, possible vaccines, animal models, and immunotherapy
Ranjan K. Mohapatra, Lucia Pintilie, Venkataramana Kandi, et al.
Chemical Biology & Drug Design (2020) Vol. 96, Iss. 5, pp. 1187-1208
Open Access | Times Cited: 127
Targeting human TLRs to combat COVID‐19: A solution?
Ritwik Patra, Nabarun Chandra Das, Suprabhat Mukherjee
Journal of Medical Virology (2020) Vol. 93, Iss. 2, pp. 615-617
Open Access | Times Cited: 118
Non‐steroidal anti‐inflammatory drugs, prostaglandins, and COVID‐19
Calum T. Robb, Marie Goepp, Adriano G. Rossi, et al.
British Journal of Pharmacology (2020) Vol. 177, Iss. 21, pp. 4899-4920
Open Access | Times Cited: 93
Potential of regulatory T-cell-based therapies in the management of severe COVID-19
Emmanuel Stephen‐Victor, Mrinmoy Das, Anupama Karnam, et al.
European Respiratory Journal (2020) Vol. 56, Iss. 3, pp. 2002182-2002182
Open Access | Times Cited: 90
Potential Therapeutic Targets and Vaccine Development for SARS-CoV-2/COVID-19 Pandemic Management: A Review on the Recent Update
Uttpal Anand, Shweta Jakhmola, Omkar Indari, et al.
Frontiers in Immunology (2021) Vol. 12
Open Access | Times Cited: 78
Host-pathogen interaction in COVID-19: Pathogenesis, potential therapeutics and vaccination strategies
Praveen M. Varghese, Anthony G. Tsolaki, Hadida Yasmin, et al.
Immunobiology (2020) Vol. 225, Iss. 6, pp. 152008-152008
Open Access | Times Cited: 77
Identification of Potent and Safe Antiviral Therapeutic Candidates Against SARS-CoV-2
Xia Xiao, Conghui Wang, De Chang, et al.
Frontiers in Immunology (2020) Vol. 11
Open Access | Times Cited: 77
Potential immuno-nanomedicine strategies to fight COVID-19 like pulmonary infections
Srinivasa Reddy Bonam, Niranjan G. Kotla, Raghvendra A. Bohara, et al.
Nano Today (2020) Vol. 36, pp. 101051-101051
Open Access | Times Cited: 69
Natural killer cells play an important role in virus infection control: Antiviral mechanism, subset expansion and clinical application
Wei Zuo, Xiaosu Zhao
Clinical Immunology (2021) Vol. 227, pp. 108727-108727
Open Access | Times Cited: 60
Type I Interferon Production of Plasmacytoid Dendritic Cells under Control
Dóra Bencze, Tünde Fekete, Kitti Pázmándi
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 8, pp. 4190-4190
Open Access | Times Cited: 58
Immune dysfunction following COVID-19, especially in severe patients
Cong-Ying Song, Jia Xu, Jianqin He, et al.
Scientific Reports (2020) Vol. 10, Iss. 1
Open Access | Times Cited: 67
Revisiting pharmacological potentials of Nigella sativa seed: A promising option for COVID‐19 prevention and cure
Mohammad Nazrul Islam, Khandkar Shaharina Hossain, Sourav Sarker, et al.
Phytotherapy Research (2020) Vol. 35, Iss. 3, pp. 1329-1344
Open Access | Times Cited: 67
Interleukin-6: Molecule in the Intersection of Cancer, Ageing and COVID-19
Jan Brábek, Milan Jakubek, F.M.D. Vellieux, et al.
International Journal of Molecular Sciences (2020) Vol. 21, Iss. 21, pp. 7937-7937
Open Access | Times Cited: 67
Page 1 - Next Page

Scroll to top